Mito-lonidamine inhibits complex I-mediated oxygen consumption, oxidation of peroxiredoxin Akt/mTOR/p7056K signaling, and induction of autophagy in lung cancer cells; Mito-magnolol decreases complex I-mediated oxygen consumption and Akt/FOXO signaling, and blocks cell cycle progression and cell proliferation in melanoma cells; and Mito-honokiol inhibits lung cancer cell proliferation through activation of AMPK and inhibition of STAT3 signaling (52). The gene discussed is STAT3; the disease is lung carcinoma.